New Research Grant For Deoxymabs in Metastatic Breast Cancer (Patrys)

Posted: 26 August 2022

Today Patrys announced that the Olivia Newton-John Cancer Research Institute (ONJCRI) has been awarded a $100,000 Victorian State Government Victorian Medical Research Acceleration Fund (VMRAF) grant to support its research investigating the potential for PAT-DX1 and PAT-DX3 to be incorporated into new treatments for metastatic breast cancer.

The research program, led by Professor Robin Anderson, Head of ONJCRI’s Translational Breast Cancer Program and Metastasis Research Laboratory, will evaluate the ability of PAT-DX1 and PAT-DX3 to control tumour growth and metastasis in preclinical models of breast cancer. It will also evaluate in animal models the use of PAT-DX1 and PAT-DX3, in combination with DNA damaging agents such as radiation and chemotherapy, for treating triple negative breast cancer.

Patrys CEO and Managing Director, Dr James Campbell, was delighted to share this news today:

“We are delighted that this VMRAF grant will allow us to expand our ongoing research program with Professor Anderson at the internationally-recognised ONJCRI. We have recently discovered that PAT-DX1 inhibits the formation of NETs, molecules that are implicated in the progression and metastasis in some cancers, and this new grant focused on metastatic breast cancer is an exciting addition to our programs.”

Click here to read today’s ASX release here.

This is the second grant Patrys and ONJCRI have been awarded to support development efforts of PAT-DX1, with a $50,000 Federal Government grant through the Entrepreneur’s Programme Innovation Connections scheme received in 2020.

As the Patrys team moves towards its goal of commencing its first in-human clinical trial, collaborations with world-class research organisations like ONJCRI provide valuable preclinical data to inform how its deoxymabs can potentially target multiple cancers.

This grant represents a strong endorsement of the importance of this research and will go a long way towards supporting the development of new approaches in cancer treatments.


News & opinion

Member Directory